Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical company in the business of developing new medicines for people living with life changing conditions, now helps more than nine million patients worldwide. Nektar also offers a proprietary pipeline made up of drug candidates for oncology, pain, anti-infectives, and immunology. The company has 12 approved products, including Movantik, Adynovate, and Onzeald.
Movantik, which is used for the treatment of opioid induced constipation, was approved for sale in both the U.S. and Europe in 2014, allowing Nektar to see a significant increase in sales and royalty payments. Adynovate, used in the treatment of hemophilia A in patients aged 12 and above, was approved for sale in the U.S. in 2015. The company also partnered with Shire, giving Nektar an extra $55,000 in sales.
Onzeald is used in the treatment of metastatic breast cancer with brain metastases. The company partnered with Daiichi Sankyo on June 1, 2016, giving Daiichi exclusive commercialization rights in the European Economic Area, Switzerland, and Turkey. This partnership could potentially give Nektar a total of $60 million in commercial and regulatory milestones.
In addition, Nektar Therapeutics recently presented new clinical data (http://dtn.fm/g8OQs) from its ongoing phase I dose-escalation study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting. The candidate is an investigatory immunostimulatory therapy that expands specific cancer fighting T-cells and natural killer cell abundance in the tumor’s microenvironment.
According to Dr. Ivan Gergel, Senior Vice President, Drug Development & Chief Medical Officer of Nektar, “NKTR-214 resulted in robust activation of the immune system and encouraging anti-tumor activity, including a partial response observed in a patient who continues to be treated with NKTR-214″. There has been evidence that seven out of the 18 patients so far have had radiographic reductions in tumor size per RECIST 1.1 on NKTR-214.
With this in mind, Aegis Capital Corp. (http://dtn.fm/cxSm0) initiated coverage on Nektar Therapeutics, offering the company a ‘Buy’ rating with a target price of $21. Areas covered in the report include the sources of revenue, details of the partnerships put in place, and an oncology clinical collaboration with BMS for evaluating the combination of Opdivo and NKTR-214. The target price was based on an EV/Sales multiple of eight, which was applied to the expected sales of $378 million by 2020.
For more information, visit the company’s website at www.nektar.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
